More Good News On Actemra In Severe COVID-19 – But Will Roche File For Approval?

Another Significant RECOVERY Result

The RECOVERY trial has found Actemra to help cut deaths and speed recovery – and UK doctors are not waiting for Roche to complete its own studies.

NHS — The RECOVERY trial's rapid and robust readouts are thanks to large-scale recruitment of COVID-19 patients across the UK's National Health Service.

Results from a large-scale academic study of Roche’s Actemra (tocilizumab) have confirmed it can help save lives of patients hospitalized with COVID-19.

The news completes a reversal of fortune for the drug in COVID-19, where a series of earlier trial failures in the midst of the 2020 pandemic had suggested it

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

09 May 2025

• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

09 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.